{"schema":"sb.node.v1","id":"sb:e/889ea976585c6da09b6e36e3","kind":"entity","label":{"text":"biological products","locale":"en"},"identity":{"anchor":"label:en:biological products","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T20:32:23.797512+00:00","snapshot":"deploy 3e7bbff4140e43a2329acde8ba02835aee4f4b00"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":67,"separatePublishers":10,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.269,"named":18,"of":67,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 27% of the 67 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-14","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.418: about 58% of mentions carry no typed assertion"]}},"dimensions":{"domains":["pharma-regulatory","biotech_pharma"],"activeDays":38,"assertions":{"regulatory-approval":27,"sports-outcome":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/a251a1bdc04c59076e29fa23","kind":"observation","label":"FDA Drug News · 2026-08-15 · Container Closure Systems for Human Drugs and Biological Products","url":"http://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-human-drugs-and-biological-products"},{"id":"sb:o/29aa53a219a890c664c7fad9","kind":"observation","label":"FDA Drug News · 2026-07-02 · [APPROVAL] Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products","url":"http://www.fda.gov/drugs/emergency-preparedness-drugs/emergency-use-authorizations-drugs-and-non-vaccine-biological-products"},{"id":"sb:o/d12e0ef3ae2f45e9877668c1","kind":"observation","label":"FDA Drug News · 2026-06-22 · Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products","url":"http://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products"},{"id":"sb:o/519bfdd631cd9de60a9b7d49","kind":"observation","label":"FDA Drug News · 2026-06-10 · Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products and Safety Reporting Requirements for Bioavailability and Bioequ…","url":"http://www.fda.gov/drugs/investigational-new-drug-ind-application/final-rule-investigational-new-drug-safety-reporting-requirements-human-drug-and-biological-products"},{"id":"sb:o/2d0dafa7e3095ae77211c16d","kind":"observation","label":"FDA D.I.S.C.O. (Drug Info Soundcast in Clinical · 2026-10-01 · Prescription Drug User Fee Amendments","url":"http://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments"},{"id":"sb:o/0e9ffcaa52cc3a7cbe15d8e6","kind":"observation","label":"GEN · 2026-09-25 · JNC Targets Bigger Molecules with Cellufine","url":"https://www.genengnews.com/topics/bioprocessing/jnc-targets-bigger-molecules-with-cellufine/"},{"id":"sb:o/9d0c524a59af5a2bed79b98c","kind":"observation","label":"Veterinary Practice News · 2026-09-23 · FDA updates rules to advance non-animal, innovative testing in human drug development","url":"https://www.veterinarypracticenews.com/fda-updates-rules-advance-non-animal-innovating-testing-drug-development/"},{"id":"sb:o/9d6bc10bb7e5cc7456aa0589","kind":"observation","label":"FDA · 2026-09-22 · FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing","url":"http://www.fda.gov/news-events/press-announcements/fda-updates-regulations-advance-innovative-alternatives-animal-testing"},{"id":"sb:o/cb2ad883fd72ac548f1b85ac","kind":"observation","label":"FDA · 2026-09-04 · Novel Drug Approvals for 2026","url":"http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026"},{"id":"sb:o/47a98b25a440dcb8bc09b8e8","kind":"observation","label":"FDA · 2026-09-03 · FDALabel: Full-Text Search of Drug Product Labeling","url":"http://www.fda.gov/science-research/bioinformatics-tools/fdalabel-full-text-search-drug-product-labeling"}],"cursor":"c1.eyJpZCI6InNiOmUvODg5ZWE5NzY1ODVjNmRhMDliNmUzNmUzIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDIwOjMyOjIzLjc5NzUxMiswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (55 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e50c9952581a37615ff7ac1c"},{"kind":"relation","label":"co-mentioned with drug administration (29 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8c2346e485c320c4aab00d7a"},{"kind":"relation","label":"co-mentioned with cder (26 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/da1ec133ff7ac579e9349c0a"},{"kind":"relation","label":"co-mentioned with drug development (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9a750c71c63012a1bc6c3077"},{"kind":"relation","label":"co-mentioned with u.s. food (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/479bb326096d1f13d9e1a5f6"},{"kind":"relation","label":"co-mentioned with clinical trials (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/742fa49febe2c538d894421e"},{"kind":"relation","label":"co-mentioned with drug evaluation (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/eb8bda366ff6daba31d76436"},{"kind":"relation","label":"co-mentioned with clinical trial (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7be9478ed9805e8a38d61c29"},{"kind":"relation","label":"co-mentioned with draft guidance (14 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0894b5377d5ccae6fe195449"},{"kind":"relation","label":"co-mentioned with cber (13 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/411eb73a79c3992499065dbe"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/889ea976585c6da09b6e36e3","mcp":"traverse {\"id\":\"sb:e/889ea976585c6da09b6e36e3\"}","page":"/entity/biological-products/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/889ea976585c6da09b6e36e3\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/889ea976585c6da09b6e36e3\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/889ea976585c6da09b6e36e3\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/889ea976585c6da09b6e36e3\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}